METHODS: 890 consecutive hospitalized HBV-related chronic liver disease patients with acute decompensation from 2005-2010 were included. Among them 243 (27%) patients underwent liver transplantation

(LT). Predisposition (cirrhosis), acute insult, inflammatory parameters (leukocyte count), CLIF-SOFA score and short-term mortality were used to evaluate the population. RESULTS: According to the CLIF-SOFA score, 24% (211/890) patients had ACLF at enrollment and 7% (62/890) developed ACLF within 28-days. Their 28 and 90-day mortality were 41%, 37% and 46%, 45% respectively. 20%, 53% and 27% patients had ACLF-1, ACLF-2 or ACLF-3. The 28 and 90-day mortality were 24% and 31%; 40% and LY2835219 44%; 53% and 61% respectively. Non-ACLF patients (69%; 617/890) had a 28 and 90-day mortality of 3% and 6% respectively (P<0.001 vs ACLF). ACLF patients had a significantly higher white cell (10±6*109 vs 5±4*109/L; find more P<0.001) compared with non-ACLF patients. No precipitating event was identifiable in 62% (130/211) ACLF and 45% (305/679) non-ACLF patients. Both HBV reactivation (30%) and bacterial infection

(30%) were the most frequent acute insult for precipitating events identifiable ACLF patients. CONCLUSION: The results confirm that the clinical characteristics of ACLF patients in China, where the main cause is HBV infection is similar to the clinical characteristics of European patients where the main etiology is alcohol. CLIF-SOFA score allows classification of ACLF into different

prognostic groups; precipitating factor is not necessary; MCE公司 infection is an important precipitating factor and systemic inflammation is pathophysiologically important. The data argue strongly that the ‘Eastern’ form of ACLF follows similar diagnostic, prognostic and pathophysiological characteristics to that of the ‘Western’ form suggesting that the definition of ACLF should be harmonized world-wide. Disclosures: Pere Gines – Advisory Committees or Review Panels: Ferring ; Grant/Research Support: Sequana Medical, Grifols Vicente Arroyo – Speaking and Teaching: GRIFOLS Rajiv Jalan – Consulting: Ocera Therapeutics, Conatus; Grant/Research Support: Grifols, Gambro The following people have nothing to disclose: Hai Li, Marco Pavesi, Bo Zeng, Liu-Ying Chen, Shu-Ting Li, De-Kai Qiu, Richard Moreau Background and Aim: Kidney dysfunction is an ominous sign in ACLF patients. There is however, limited data on predictors of kidney dysfunction in ACLF. The PIRO classification was developed to stratify patients with sepsis with different outcomes. We developed a modified PIRO model (Predisposition,Injury,Response,Organ failure) to identify variables for predicting kidney failure in a multicentric, multinational cohort of ACLF patients(APASL definition).